Dr. Patricia Hurter serves as CEO of Lyndra Therapeutics, a biotechnology company pioneering oral long-acting therapies to make daily pills a thing of the past. Lyndra’s lead product is oral weekly risperidone for schizophrenia and bipolar disorder, with several other products in development.
Prior to Lyndra, she spent 15 years at Vertex, bringing multiple breakthrough therapies to market. At Vertex, her team designed and built the world’s first fully continuous drug product manufacturing plant, approved by the FDA in 2015. Before joining Vertex, Dr. Hurter was Director of Formulation at Merck, where she was a key member of the early development team for Januvia®.
Dr Hurter serves on the Board of Directors of Lyndra Therapeutics, and Synlogic Therapeutics, a publicly traded company pioneering the application of synthetic biology to design living therapeutics. She is a member of the Advisory Board of the Taubman Center for State and Local Government at the Harvard Kennedy Center. She holds a Ph.D. in chemical engineering from MIT, an M.S. in mechanical engineering from WVU and a B.Sc. in chemical engineering, cum laude, from the University of KwaZulu-Natal (South Africa). She is a member of the National Academy of Engineering.
Co-sponsored by AIChE Management Division.
To attend the webinar you must REGISTER IN ADVANCE by clicking the link below. Once there, select "CHECKOUT" in the top right and purchase the webinar, which is FREE to AIChE members.
- Log in to post comments